Pricing Log in Create free account

AbCellera Biologics Inc. (ABCL) vs Parabilis Medicines, Inc. (PBLS)

AbCellera Biologics Inc. and Parabilis Medicines, Inc. are both Biotechnology companies. AbCellera Biologics Inc. and Parabilis Medicines, Inc. are of similar size ($3.6B and $3.4B). Parabilis Medicines, Inc. has the higher net margin (0.00% vs −248.8%) and the higher return on invested capital (0.00% vs −42.5%). Across the 13 metrics below, Parabilis Medicines, Inc. leads on 9 and AbCellera Biologics Inc. on 4.

Valuation

Metric ABCL PBLS Biotechnology median
P/E n/m n/m 10.26
P/S 51.95 n/m 9.18
P/B 3.84 0.77 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m 1.79 0.65
EV/Sales 43.46 n/m 8.98
Earnings yield (4.80%) (297.78%) (34.89%)
Free cash flow yield (3.57%) (14.78%) (24.52%)

Profitability

Metric ABCL PBLS Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (340.25%) 0.00% 0.00%
Net margin (248.82%) 0.00% 0.00%
Free cash flow margin (180.84%) 0.00% 0.00%
Return on equity (17.30%) 0.00% (50.12%)
Return on assets (12.15%) 0.00% (45.60%)
Return on invested capital (42.52%) 0.00% 0.00%

Growth

Metric ABCL PBLS Biotechnology median
Revenue growth (TTM) 101.29% — 6.26%
EPS growth (last fiscal year) 10.91% (10.69%) 29.88%
Revenue growth, 5-year CAGR (20.27%) — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ABCL PBLS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 12.77 17.91 4.89
Net debt to EBITDA 2.97 0.09 1.01

Dividend

Metric ABCL PBLS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ABCL PBLS Biotechnology median
Market cap 3.61b 3.44b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack